MedTrace Logo

A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China

NCT04614597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 774

Last updated 2022-03-09

No results posted yet for this study

Summary

In 2017, China CDC conducted a study titled "A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China". At present, all the infants in the monitoring cohort were over 18 months old and at least one year had elapsed since the last dose of sIPV inoculation.Since there is no any data about the protection duration of two-dose Sabin IPV schedules, China CDC propose to follow up the study cohort to evaluate the proportion of seroprotection of antibody and measure neutralizing antibody titers against poliovirus at over 18 months of age infants after a 2-dose or a 3-dose primary schedule of Sabin IPV in Chinese children.

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

Sabin strain inactivated polio vaccine

Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.

Sponsors & Collaborators

  • World Health Organization

    collaborator OTHER

  • Shandong Province Centers for Disease Control and Prevention

    collaborator OTHER

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Zijian Feng, MD · Centers for Disease Control and Prevention, China

  • Zhijie An, MPH · Centers for Disease Control and Prevention, China

  • Zundong Yin · Centers for Disease Control and Prevention, China

Eligibility

Min Age
18 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2021-12-21
Completion
2021-12-21

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04614597 on ClinicalTrials.gov